Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial

Yoshiteru Takekita, Yosuke Koshikawa, Chiara Fabbri, Shiho Sakai, Naotaka Sunada, Ai Onohara, Keiichiro Nishida, Masafumi Yoshimura, Masaki Kato, Alessandro Serretti, Toshihiko Kinoshita, Yoshiteru Takekita, Yosuke Koshikawa, Chiara Fabbri, Shiho Sakai, Naotaka Sunada, Ai Onohara, Keiichiro Nishida, Masafumi Yoshimura, Masaki Kato, Alessandro Serretti, Toshihiko Kinoshita

Abstract

Background: Recently, long-acting injection (LAI) of second-generation antipsychotics has become a valuable strategy for the treatment of schizophrenia. However, few studies have compared the effects of different LAI antipsychotics on cognitive functions so far. The present study aimed to compare the influence of risperidone LAIs (RLAI) and paliperidone palmitate LAIs (PP) on cognitive function in outpatients with schizophrenia.

Methods: In this 6-month, open-label, randomized, and controlled study, 30 patients with schizophrenia who were treated with RLAIs were randomly allocated to the RLAI-continued group or the PP group. At baseline and 6 months, the patients were evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) that was the primary outcome of the study. The Subjective Well-being under Neuroleptic drug treatment-Short form (SWNS), the Positive and Negative Syndrome Scale (PANSS), and the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores were secondary outcome variables and they were tested at the same time points.

Results: The two groups did not differ in terms of PANSS, DIEPSS, or SWNS total score changes. However, the BACS score for the attention and processing speed item showed higher improvement in the PP group than the RLAI group (p = 0.039).

Conclusions: The results of this preliminary study suggest that PPs may improve attention and processing speed more than RLAIs. Anyway, a replication in a larger and double-blind study is needed.

Trial registration: UMIN000014470 . Registered 10 July 2014.

Keywords: Cognitive function; Efficacy; Paliperidone palmitate; Risperidone long-acting injection; Schizophrenia; Subjective well-being.

Figures

Fig. 1
Fig. 1
CONSORT flow of participants through the trial

References

    1. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry. 1996;57(Suppl 11):68–71.
    1. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609–615. doi: 10.1176/appi.ajp.2013.12050674.
    1. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071. doi: 10.1016/S0140-6736(12)60239-6.
    1. Mojtabai R, Lavelle J, Gibson PJ, Sohler NL, Craig TJ, Carlson GA, Bromet EJ. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv. 2002;53(3):337–339. doi: 10.1176/appi.ps.53.3.337.
    1. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–891. doi: 10.1176/appi.ps.55.8.886.
    1. Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a 6-month naturalistic follow-up study. Schizophr Res. 2011;130(1–3):176–181. doi: 10.1016/j.schres.2011.04.030.
    1. Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, Schimmelmann BG, Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatr. 2007;68(1):75–80. doi: 10.4088/JCP.v68n0110.
    1. McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, Rossler W, Salize HJ, Svensson B, Torres-Gonzalez F, van den Brink R, et al. The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One. 2012;7(4):e36080. doi: 10.1371/journal.pone.0036080.
    1. Moritz S, Hunsche A, Lincoln TM. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms. Eur Neuropsychopharmacol. 2014;24(11):1745–1752. doi: 10.1016/j.euroneuro.2014.09.008.
    1. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14(2):87–92. doi: 10.1016/S0924-977X(03)00109-3.
    1. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. doi: 10.4088/JCP.13r08440.
    1. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007;12(10):904–922. doi: 10.1038/sj.mp.4002062.
    1. Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, Kim JM, Shin IS, Yoon JS. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol. 2012;27(5):267–274. doi: 10.1097/YIC.0b013e328356acad.
    1. Suzuki H, Gen K, Inoue Y, Hibino H, Mikami A, Matsumoto H, Mikami K. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Int J Psychiatry Clin Pract. 2014;18(1):58–62. doi: 10.3109/13651501.2013.845218.
    1. Green MF, Barnes TR, Danion JM, Gallhofer B, Meltzer HY, Pantelis C. The FOCIS international survey on psychiatrists’ opinions on cognition in schizophrenia. Schizophr Res. 2005;74(2–3):253–261. doi: 10.1016/j.schres.2004.05.023.
    1. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci. 2007;61(6):602–609. doi: 10.1111/j.1440-1819.2007.01725.x.
    1. Suzuki H, Gen K. The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Ther Adv Psychopharmacol. 2012;2(1):23–29. doi: 10.1177/2045125311430536.
    1. Suzuki H, Gen K. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Hum Psychopharmacol. 2012;27(5):470–475. doi: 10.1002/hup.2249.
    1. Hori H, Noguchi H, Hashimoto R, Okabe S, Saitoh O, Kunugi H. IQ decline and memory impairment in Japanese patients with chronic schizophrenia. Psychiatry Res. 2008;158(2):251–255. doi: 10.1016/j.psychres.2007.11.002.
    1. Drug information of paliperidone palmitate. Interview form of XEPLION® Aqueous Suspension for IM Injection 7th edition []. Accessed 3 Apr 2016.
    1. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(Suppl 3):133–138.
    1. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1–2):79–88. doi: 10.1016/S0920-9964(00)00166-3.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261.
    1. Inada T. Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage. Tokyo: Seiwa Shoten; 1996.
    1. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2–3):283–297. doi: 10.1016/j.schres.2003.09.011.
    1. Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. J Psychiatr Res. 2012;46(6):757–761. doi: 10.1016/j.jpsychires.2012.02.013.
    1. Hori H, Yoshimura R, Katsuki A, Sugita AI, Atake K, Nakamura J. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. J Psychiatr Res. 2013;47(12):1843–1848. doi: 10.1016/j.jpsychires.2013.08.024.
    1. Kaneda Y, Sumiyoshi T, Nakagome K, Numata S, Tanaka T, Ueoka Y, Omori T, Keefe R. The brief assessment of cognition in schizophrenia Japanese version (BACS-J) Seishinigaku. 2008;50(9):913–917.
    1. Watanabe M, Matsumura H. Reliability and validity of Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) Jpn J Clin Psychopharmacol. 2003;6(7):905–912.
    1. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004;55(10):1013–1022. doi: 10.1016/j.biopsych.2004.01.027.
    1. Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013;39(3):564–74.
    1. Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, Menon M, Mamo DC. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009;29(6):571–575. doi: 10.1097/JCP.0b013e3181bf4ea3.
    1. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007;89(1–3):211–224. doi: 10.1016/j.schres.2006.08.021.
    1. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. 2013;39(5):993–998. doi: 10.1093/schbul/sbt090.
    1. Ogino S, Miyamoto S, Tenjin T, Kitajima R, Ojima K, Miyake N, Funamoto Y, Arai J, Tsukahara S, Ito Y, et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):78–83. doi: 10.1016/j.pnpbp.2010.08.030.
    1. Kitajima R, Miyamoto S, Tenjin T, Ojima K, Ogino S, Miyake N, Fujiwara K, Funamoto Y, Arai J, Tsukahara S, et al. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):300–306. doi: 10.1016/j.pnpbp.2011.11.008.
    1. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):457–472. doi: 10.1017/S146114570500516X.
    1. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1061–1071. doi: 10.1176/ajp.2007.164.7.1061.
    1. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST) Am J Psychiatry. 2009;166(6):675–682. doi: 10.1176/appi.ajp.2008.08060806.
    1. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3):249–258. doi: 10.1001/archpsyc.57.3.249.
    1. Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. CNS Drugs. 2012;26(11):975–982. doi: 10.1007/s40263-012-0003-4.
    1. Desamericq G, Schurhoff F, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi AC, Maison P. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014;70(2):127–134. doi: 10.1007/s00228-013-1600-y.
    1. Nesvag R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand. 2006;114(1):21–26. doi: 10.1111/j.1600-0447.2006.00840.x.
    1. Franberg O, Marcus MM, Svensson TH. Involvement of 5-HT2A receptor and alpha2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse. 2012;66(7):650–660. doi: 10.1002/syn.21551.
    1. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(4):433–441. doi: 10.1017/S1461145709990897.
    1. Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, A, Weizman R. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003;13(2):123–8.
    1. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurol. 2009;10(3):211–223. doi: 10.1038/nrn2573.
    1. Sheehan JJ, Reilly KR, Fu DJ, Alphs L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7–8):17–23.
    1. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi: 10.1016/S0140-6736(13)60733-3.
    1. Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry. 2006;63(11):1189–1197. doi: 10.1001/archpsyc.63.11.1189.
    1. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218–226. doi: 10.1016/j.pnpbp.2010.11.008.
    1. Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15(1):107–118. doi: 10.1017/S1461145711001076.
    1. Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol. 2014;29(1):45–55. doi: 10.1097/YIC.0000000000000006.
    1. Gross JJ. Emotion regulation in adulthood: Timing is everything. Curr Dir Psychol Sci. 2001;10(6):214–219. doi: 10.1111/1467-8721.00152.
    1. Ferri J, Schmidt J, Hajcak G, Canli T. Neural correlates of attentional deployment within unpleasant pictures. Neuroimage. 2013;70:268–277. doi: 10.1016/j.neuroimage.2012.12.030.
    1. Hajcak G, MacNamara A, Foti D, Ferri J, Keil A. The dynamic allocation of attention to emotion: simultaneous and independent evidence from the late positive potential and steady state visual evoked potentials. Biol Psychol. 2013;92(3):447–455. doi: 10.1016/j.biopsycho.2011.11.012.
    1. Strauss GP, Kappenman ES, Culbreth AJ, Catalano LT, Ossenfort KL, Lee BG, Gold JM. Emotion Regulation Abnormalities in Schizophrenia: Directed Attention Strategies Fail to Decrease the Neurophysiological Response to Unpleasant Stimuli. J Abnorm Psychol. 2014;124(2):288–301. doi: 10.1037/abn0000017.
    1. Pazvantoglu O, Simsek OF, Aydemir O, Sarisoy G, Boke O, Ucok A. Factor structure of the Subjective Well-being under Neuroleptic treatment Scale-short form in schizophrenic outpatients: five factors or only one? Nord J Psychiatry. 2014;68(4):259–265. doi: 10.3109/08039488.2013.807875.
    1. Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron JC. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encéphale. 2005;31(5 Pt 1):609–615. doi: 10.1016/S0013-7006(05)82420-0.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel